Your browser doesn't support javascript.
loading
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.
Sade-Feldman, Moshe; Yizhak, Keren; Bjorgaard, Stacey L; Ray, John P; de Boer, Carl G; Jenkins, Russell W; Lieb, David J; Chen, Jonathan H; Frederick, Dennie T; Barzily-Rokni, Michal; Freeman, Samuel S; Reuben, Alexandre; Hoover, Paul J; Villani, Alexandra-Chloé; Ivanova, Elena; Portell, Andrew; Lizotte, Patrick H; Aref, Amir R; Eliane, Jean-Pierre; Hammond, Marc R; Vitzthum, Hans; Blackmon, Shauna M; Li, Bo; Gopalakrishnan, Vancheswaran; Reddy, Sangeetha M; Cooper, Zachary A; Paweletz, Cloud P; Barbie, David A; Stemmer-Rachamimov, Anat; Flaherty, Keith T; Wargo, Jennifer A; Boland, Genevieve M; Sullivan, Ryan J; Getz, Gad; Hacohen, Nir.
Afiliación
  • Sade-Feldman M; Massachusetts General Hospital Cancer Center, Harvard Medical School (HMS), Boston, MA, USA; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA; Department of Medicine, Massachusetts General Hospital, HMS, Boston, MA, USA.
  • Yizhak K; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Bjorgaard SL; Massachusetts General Hospital Cancer Center, Harvard Medical School (HMS), Boston, MA, USA; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Ray JP; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • de Boer CG; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Jenkins RW; Massachusetts General Hospital Cancer Center, Harvard Medical School (HMS), Boston, MA, USA; Department of Medicine, Massachusetts General Hospital, HMS, Boston, MA, USA; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
  • Lieb DJ; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Chen JH; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA; Department of Pathology, Massachusetts General Hospital, HMS, Boston, MA, USA.
  • Frederick DT; Massachusetts General Hospital Cancer Center, Harvard Medical School (HMS), Boston, MA, USA.
  • Barzily-Rokni M; Massachusetts General Hospital Cancer Center, Harvard Medical School (HMS), Boston, MA, USA.
  • Freeman SS; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA; Department of Biomedical Informatics, HMS, Boston, MA, USA.
  • Reuben A; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hoover PJ; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA; Brigham & Women's Hospital, Division of Rheumatology, Immunology and Allergy, Boston, MA, USA.
  • Villani AC; Massachusetts General Hospital Cancer Center, Harvard Medical School (HMS), Boston, MA, USA; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA; Department of Medicine, Massachusetts General Hospital, HMS, Boston, MA, USA.
  • Ivanova E; Department of Medicine, Massachusetts General Hospital, HMS, Boston, MA, USA; Belfer Center for Applied Cancer Science, Dana Farber Cancer Institute, Boston, MA, USA.
  • Portell A; Department of Medicine, Massachusetts General Hospital, HMS, Boston, MA, USA; Belfer Center for Applied Cancer Science, Dana Farber Cancer Institute, Boston, MA, USA.
  • Lizotte PH; Department of Medicine, Massachusetts General Hospital, HMS, Boston, MA, USA; Belfer Center for Applied Cancer Science, Dana Farber Cancer Institute, Boston, MA, USA.
  • Aref AR; Department of Medicine, Massachusetts General Hospital, HMS, Boston, MA, USA; Belfer Center for Applied Cancer Science, Dana Farber Cancer Institute, Boston, MA, USA.
  • Eliane JP; Department of Pathology, Massachusetts General Hospital, HMS, Boston, MA, USA.
  • Hammond MR; Massachusetts General Hospital Cancer Center, Harvard Medical School (HMS), Boston, MA, USA.
  • Vitzthum H; Massachusetts General Hospital Cancer Center, Harvard Medical School (HMS), Boston, MA, USA.
  • Blackmon SM; Massachusetts General Hospital Cancer Center, Harvard Medical School (HMS), Boston, MA, USA.
  • Li B; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA; Department of Virology, Harvard Medical School, Boston, MA, USA.
  • Gopalakrishnan V; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Reddy SM; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Cooper ZA; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Paweletz CP; Department of Medicine, Massachusetts General Hospital, HMS, Boston, MA, USA; Belfer Center for Applied Cancer Science, Dana Farber Cancer Institute, Boston, MA, USA.
  • Barbie DA; Department of Medicine, Massachusetts General Hospital, HMS, Boston, MA, USA.
  • Stemmer-Rachamimov A; Department of Pathology, Massachusetts General Hospital, HMS, Boston, MA, USA.
  • Flaherty KT; Massachusetts General Hospital Cancer Center, Harvard Medical School (HMS), Boston, MA, USA; Department of Medicine, Massachusetts General Hospital, HMS, Boston, MA, USA.
  • Wargo JA; Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Boland GM; Massachusetts General Hospital Cancer Center, Harvard Medical School (HMS), Boston, MA, USA; Department of Surgery, Massachusetts General Hospital, HMS, Boston, MA, USA.
  • Sullivan RJ; Massachusetts General Hospital Cancer Center, Harvard Medical School (HMS), Boston, MA, USA; Department of Medicine, Massachusetts General Hospital, HMS, Boston, MA, USA.
  • Getz G; Massachusetts General Hospital Cancer Center, Harvard Medical School (HMS), Boston, MA, USA; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA; Department of Pathology, Massachusetts General Hospital, HMS, Boston, MA, USA; Department of Pathology, Harvard
  • Hacohen N; Massachusetts General Hospital Cancer Center, Harvard Medical School (HMS), Boston, MA, USA; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA; Department of Medicine, Massachusetts General Hospital, HMS, Boston, MA, USA. Electronic address: nhacohen@mgh.
Cell ; 175(4): 998-1013.e20, 2018 11 01.
Article en En | MEDLINE | ID: mdl-30388456
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Linfocitos T CD8-positivos / Transcriptoma / Inmunoterapia / Melanoma Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Cell Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Linfocitos T CD8-positivos / Transcriptoma / Inmunoterapia / Melanoma Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Cell Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos